March 7th 2025
The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
December 29th 2021A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.
Copanlisib Plus Rituximab May Be ‘Viable Option’ Across Indolent Non-Hodgkin Lymphoma
July 16th 2021More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.
Assessment Predicts Survival In Elderly Patients with DLBCL
April 2nd 2021A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.
CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning
November 29th 2020Following the approvals of tisagenlecleucel (tisa-cel; Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta), several research efforts have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas, according to Olalekan O. Oluwole, MBBS, MD, who added that although this modality has moved the needle forward, this approach is not without toxicity.
Investigational CAR T-Cell Product Plus Immunotherapy Is Active in DLBCL
September 26th 2020The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
High-Risk Biology Associated With Poorer Outcomes in MCL
September 20th 2020Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.